Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Study Details
Study Description
Brief Summary
SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This Phase 2 study will evaluate the efficacy and safety of sacrosidase and placebo in male and female subjects aged 18 years or older objectively diagnosed with fructan intolerance via fructan breath test within 2 years prior to informed consent and are negative for inflammatory bowel disease or low-grade GI bacterial infection, detected by fecal calprotectin test, celiac disease, detected by serology for anti-gluten protein antibodies, congenital sucrase-isomaltase deficiency (CSID), detected by sucrose hydrogen-methane breath test, and have a negative result for abnormal uncontrolled thyroid function, detected by the standard TSH blood test. This study will consist of a Screening Visit, Baseline Period, Treatment Period 1, Washout Period, and Treatment Period 2. Subjects will be required to attend 5 clinic visits during study participation. Subjects will be randomized in a 1:1 fashion to either receive sacrosidase or placebo during Treatment Period 1. Following a 7-day Washout Period, subjects will receive their crossover study medication for Treatment Period 2. Subjects will take their assigned study medication for 7 days during each Treatment Period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Subjects will be randomized to take active treatment, sacrosidase, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week. |
Drug: Sacrosidase Oral Solution
Study drug
Other Names:
|
| Placebo Comparator: Placebo Subjects will be randomized to take placebo treatment, sacrosidase placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week. |
Drug: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- Change in incidence and severity of gastrointestinal symptoms in subjects with fructan intolerance treated with sacrosidase and placebo [Up to 7 weeks]
Change from baseline as determined by the Daily Symptom Questionnaire Total Symptom Score (TSS) rating severity on a scale from 0 to 9 and frequency on a scale from 0 to 5, based on a mean value of combination scores for, incidence of seven GI symptoms experienced in the past 24 hours during a 7-day period and severity of seven GI symptoms experienced in the past 24 hours during a 7-day period.
Secondary Outcome Measures
- Change in incidence and severity of abdominal pain in subjects with fructan intolerance treated with sacrosidase and placebo [Up to 7 weeks]
Change from baseline as determined by the Daily Symptom Questionnaire Total Symptom Score (TSS) rating severity on a scale from 0 to 9 and frequency on a scale from 0 to 5, based on a mean value of combination scores for, incidence of abdominal pain experienced in the past 24 hours during a 7-day period and severity of abdominal pain experienced in the past 24 hours during a 7-day period.
- Assess the safety and tolerability of sacrosidase compared to placebo in subjects with fructan intolerance [Up to 1 year]
Frequency and severity of treatment emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) and any premature study withdrawals related to adverse reactions
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability to comprehend and provide a signed and dated informed consent form
-
Stated willingness to comply with all study procedures and attend all scheduled clinic visits, and continue participation for the duration of the study
-
Ability to self-administer oral medication and willingness to adhere to the medication regimen
-
Male or non-pregnant, non-lactating female, at least 18 years of age
-
Sexually active women of childbearing potential must agree to use at least one reliable method of birth control while participating in the study
-
Presence of fructan intolerance as determined by a positive result on a FBT within the last 2 years
-
Subjects who are lactose intolerant agree to eliminate all lactose from their diet during the study
-
Stated willingness to discontinue any medications to resolve GI symptoms (digestive enzymes, antacids, proton pump inhibitors, histamine-2 blockers, promotility agents, or anti-diarrheal agents, etc.), per the investigator's discretion.
-
Stated willingness to discontinue any over the counter or prescribed oral nonsteroidal anti-inflammatory drugs (NSAIDs) during the study
-
Per the discretion of the investigator, absence of any GI disorder other than a diagnosis of fructan intolerance
Exclusion Criteria:
-
History of inflammatory bowel disease or active low-grade GI bacterial infection, as diagnosed by the presence of fecal calprotectin
-
History of celiac disease, as diagnosed by serology testing for anti-gluten protein antibodies
-
History of CSID, as diagnosed by the sucrose hydrogen-methane breath test,
-
Abnormal uncontrolled thyroid function, detected by abnormal TSH level in the blood
-
Per the discretion of the investigator, history of a serious physical or mental disorder
-
BMI greater than 30 kg/m2
-
History of diabetes
-
History of hypersensitivity to yeast, yeast products, glycerin (glycerol), or papain
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- QOL Medical, LLC
Investigators
- Principal Investigator: Weng Tao, M.D., Ph. D, QOL Medical, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SSDXA-14